Statistics from Altmetric.com
MULTIPLE SCLEROSIS AND FUMERATE
In patients with relapsing-remitting multiple sclerosis, treatment with oral fumarate (BG00012) 240 mg three times daily reduced by 69% the mean total number of new gadolinium enhancing lesions from week 12 to 24 compared with placebo (1.4 vs 4.5, p<0.0001). It also reduced significantly the number of new or enlarging T2-hyperintense and new T1-hypointense lesions. These are the findings of a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Abdominal pain, flushing and hot flushes were more common in patients given fumarate than those given placebo while headache, fatigue and feeling hot were dose-related adverse events.
MORE ON MULTIPLE SCLEROSIS—ALEMTUZUMAB
Treatment with alemtuzumab was suspended after immune thrombocytopenic purpura developed in three patients, one of whom died, in a phase 2, randomised, blinded trial involving patients with relapsing-remitting multiple sclerosis. The trial, which compared alemtuzumab with interferon beta-1a, found that the mean …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.